---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-055649"
form_type: "8-K"
ticker: "DFTX"
cik: "0001813814"
company_name: "Definium Therapeutics, Inc."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T12:27:16.253646+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# MindMed reports Q1 net loss $54.4M; MM120 GAD trial hits key endpoint, FDA Breakthrough Therapy

## Summary
- Net loss $54.4M Q1'24 (vs $24.8M); includes $27.7M warrant fair value change. R&D $11.7M, G&A $10.5M.
- Cash $252.3M at Mar 31 (vs $99.7M Dec'23). Expects funding into 2026.
- Phase 2b MM120 GAD: 7.7-pt HAM-A improvement vs placebo (p<0.003), 65% response, 48% remission at Week 12.
- FDA Breakthrough Therapy for MM120 in GAD. Phase 3 initiation planned H2 2024.
- CFO Schond Greenway departed May 3. Executive search for new CFO underway.

## SEC filing metadata
- accession: 0000950170-24-055649
- form_type: 8-K
- ticker: DFTX
- cik: 0001813814
- company_name: Definium Therapeutics, Inc.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1813814/000095017024055649/0000950170-24-055649-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1813814/000095017024055649/mnmd-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-055649
- JSON: https://secwatch.observer/filing/0000950170-24-055649.json
- Plain text: https://secwatch.observer/filing/0000950170-24-055649.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.